2seventy bio and Bristol Myers Squibb Discontinue Phase 3 KarMMa-9 Study Enrollment Amid Promising Q3 Financial Outlook
CAMBRIDGE, Mass.’ - 2seventy bio, Inc. (Nasdaq: TSVT) recently announced a significant strategic development in collaboration with Bristol Myers Squibb (BMS). The two companies have decided to discontinue enrollment in the ongoing Phase 3 KarMMa-9 study, which examines the efficacy of Abecma (idecabtagene vicleucel; ide-cel) in combination with lenalidomide maintenance, compared to lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have had a suboptimal response to autologous stem cell transplant.
The KarMMa-9 study, which aimed to investigate a pivotal treatment avenue for NDMM patients, encountered unforeseen challenges that influenced the decision to halt further participant enrollment. Although the specific factors affecting this decision have not been disclosed in detail, the collaborative nature of the discontinuation suggests both firms are redirecting their focus based on comprehensive, ongoing evaluations.
This strategic pivot comes at a time when 2seventy bio is poised to report a strong financial performance for the third quarter. The anticipated revenue growth underscores the company’s resilient market position and robust portfolio of oncology treatments. The positive financial outlook is expected to bolster investor confidence and further highlight 2seventy bio’s long-term value proposition.
Our decision to discontinue enrollment in the KarMMa-9 study is rooted in a commitment to optimizing patient outcomes and effectively utilizing our resources, said Dr. Nick Leschly, CEO of 2seventy bio. Concurrently, our promising revenue performance this quarter reflects our focus on operational excellence and the successful execution of our strategic initiatives.
Collaboration remains a cornerstone of 2seventy bio’s approach, as evidenced by their ongoing partnership with industry giant Bristol Myers Squibb. Together, the companies continue to explore novel therapeutic avenues and deliver transformational treatments to cancer patients worldwide.
The biopharmaceutical landscape continues to evolve, and companies like 2seventy bio and BMS are at the forefront, driving innovations that have the potential to redefine standards of care. Halting the KarMMa-9 study enrollment is a testament to their agility and focus on delivering meaningful clinical advancements.
In summary, while the discontinuation of the KarMMa-9 study marks a significant juncture, 2seventy bio’s robust third-quarter financial outlook reflects the company’s undeterred progress and enduring commitment to advancing oncology therapies.
End of
Comments